These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31922479)

  • 1. Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review.
    Bassendine MF; Bridge SH
    Eur J Rheumatol; 2020 Jan; 7(1):37-40. PubMed ID: 31922479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of polymyalgia rheumatica following influenza B infection.
    Iwata K; Mizuno Y
    Int J Gen Med; 2015; 8():345-7. PubMed ID: 26527896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature.
    Soriano A; Verrecchia E; Marinaro A; Giovinale M; Fonnesu C; Landolfi R; Manna R
    Lupus; 2012 Feb; 21(2):153-7. PubMed ID: 22235046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymyalgia Rheumatica Following Respiratory Syncytial Virus (RSV) Vaccination.
    El Labban M; Oluic S; Guleid H; Hassan M; Diab R; Rida MA
    Eur J Case Rep Intern Med; 2024; 11(7):004636. PubMed ID: 38984193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fever of unknown origin following parathyroidectomy prior to onset of typical polymyalgia rheumatica symptoms: a case report.
    Kanzaki A; Matsui K; Sukenaga T; Mase K; Nishioka A; Tamori T; Kataoka S; Konya H; Mizutani S; Takeda A; Koseki M; Nishiura T; Koyama H; Sano H
    Int J Gen Med; 2018; 11():307-311. PubMed ID: 30038516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following COVID-19 vaccines: working notes from a narrative review of published literature.
    Manzo C; Castagna A; Isetta M
    Reumatologia; 2022; 60(2):142-147. PubMed ID: 35782034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of trivalent influenza vaccines in patients with chronic kidney disease undergoing hemodialysis: MF59-adjuvanted versus non-adjuvanted vaccines.
    Noh JY; Song JY; Choi WS; Lee J; Seo YB; Kwon YJ; Ko GJ; Cha DR; Kang YS; Lee YK; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016 Nov; 12(11):2902-2908. PubMed ID: 27802078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Technical guidelines for seasonal influenza vaccination in China, 2019-2020].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1333-1349. PubMed ID: 31838802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications.
    Patel SS; Bizjajeva S; Heijnen E; Oberye J
    Int J Infect Dis; 2019 Aug; 85S():S18-S25. PubMed ID: 31051279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report of transient polymyalgia rheumatica after receiving the first dose of the BNT162b2 mRNA COVID-19 vaccine.
    Matsuzono K; Fujimoto S
    SAGE Open Med Case Rep; 2024; 12():2050313X241235830. PubMed ID: 38444691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature.
    Macchioni P; Boiardi L; Catanoso M; Pulsatelli L; Pipitone N; Meliconi R; Salvarani C
    Semin Arthritis Rheum; 2013 Aug; 43(1):113-8. PubMed ID: 23433960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.
    Kato K; Mizuno T; Koseki T; Ito Y; Takahashi K; Tsuboi N; Yamada S
    Front Pharmacol; 2022; 13():803706. PubMed ID: 35401222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.